



October 27, 2026

Santen Announces Change of Major Shareholder

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito; hereinafter, the “Company”) hereby announces that a major shareholder of the Company has changed on October 23, 2026 as below.

1. Background of the Changes

The Company has confirmed the change of holding shares of a major shareholder based on the Large Shareholding Report (Change Report) submitted by the shareholder below to the Kanto Regional Finance Bureau on October 26, 2026.

2. Description of Shareholder

(1) Name of shareholder	Silchester International Investors LLP
(2) Address	The Metcalf, 83-85 Pall Mall, 3 rd Floor, London SW1Y 5ES, United Kingdom
(3) Representative	Timothy Linehan, Chairperson, Business Supervisory Group
(4) Description of business	Investment advisory business

3. Number and Percentage of Voting Rights owned by the Shareholder

	Voting rights owned by Shareholder	Percentage of outstanding shares	Shareholder ranking
Before (as of October 7, 2025)	315,605 (31,560,500 shares)	9.72%	-
After (as of October 23, 2026)	330,503 (33,050,300 shares)	10.27%	-

Note1.

The above information is based on the Large Shareholding Report (Amendment Report) submitted by the shareholder in question, and the Company has not confirmed the actual number of shares beneficially owned under the shareholder’s name. Furthermore, since the Company has not confirmed the ranking of shareholders, it has not been included.

Note 2.

Percentage of total shareholder voting rights “Before” is calculated based on the total number of shares issued and outstanding as of September 30, 2025, which is 342,068,554 shares, less the number of shares not subject to voting rights of 17,303,054 shares, which is 3,247,655 of total

shareholder voting rights.

Note 3.

Percentage of total shareholder voting rights “After” is calculated based on the total number of shares issued and outstanding as of September 30, 2026, which is 322,314,154 shares, less the number of shares not subject to voting rights of 602,354 shares, which is 3,217,118 of total shareholder voting rights.

Note 4.

Percentage of total shareholder voting rights is rounded to the nearest third decimal place.

4. Outlook for the Future

Nothing in particular.

Contact:

Guillaume Sakuma

Global Head of Investor Relations

E-mail: ir@santen.com

About Santen

Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen’s products and services are available in more than 60 countries and regions. Guided by its Core Principle “*Tenki ni sanyo suru*” – Exploring the secrets and mechanisms of nature in order to contribute to people’s health – Santen combines its expertise with deep patient focus to contribute to the realization of “Happiness with Vision.”

For more information, please visit <https://www.santen.com/en>.